REG - Indivior PLC - Final Court Approval Concludes Antitrust MDL

IndiviorAnnouncement

29/02/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240229:nRSc8632Ea&default-theme=true

RNS Number : 8632E  Indivior PLC  29 February 2024

Court Provides Final Approval of Settlement with Direct Purchaser Class in the
Multidistrict Antitrust Litigation; Final Court Approval Concludes the
Antitrust Multidistrict Litigation

 

Richmond, VA, February 29, 2024 - Indivior PLC (LSE: INDV; Nasdaq: INDV), a
leading addiction treatment company, today announced that its subsidiary,
Indivior Inc., has received final Court approval for its settlement with the
Direct Purchaser class, concluding the anti-trust multi-district litigation
("MDL") matter.

 

On October 22, 2023, Indivior Inc. entered into a settlement agreement with
the remaining Direct Purchaser class for $385m. On February 27, 2024, the
United States District Court for the Eastern District of Pennsylvania entered
an order granting final judgement and order of dismissal approving the Direct
Purchaser class settlement and dismissing the Direct Purchaser class claims.
This ruling concludes the Antitrust MDL.

 

About Indivior

Indivior is a global pharmaceutical company working to help change patients'
lives by developing medicines to treat addiction and serious mental illnesses.
Our vision is that all patients around the world will have access to
evidence-based treatment for the chronic conditions and co-occurring disorders
of substance use disorder (SUD). Indivior is dedicated to transforming SUD
from a global human crisis to a recognized and treated chronic disease.
Building on its global portfolio of OUD treatments, Indivior has a pipeline of
product candidates designed to both expand on its heritage in this category
and potentially address other chronic conditions and co-occurring disorders of
SUD, including alcohol use disorder and cannabis use disorder. Headquartered
in the United States in Richmond, VA, Indivior employs more than 1,100
individuals globally and its portfolio of products is available in 37
countries worldwide. Visit www.indivior.com to learn more. Connect with
Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

 

Media Contacts:

US Media:

Cassie France-Kelly

Vice President, Communications

Indivior PLC

Tel: 804-724-0327

 

UK Media:

Teneo

Tel: +44 207-353-4200

 

Investors and Analysts:

Jason Thompson

Vice President, Investor Relations

Indivior PLC

Tel: 804-402-7123

 

Tim Owens

Director, Investor Relations

Indivior PLC

Tel: 804-263-3978

 

 

-ends-

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBIGDDBXDDGSI